Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) – Analysts at Cantor Fitzgerald upped their FY2022 earnings per share (EPS) estimates for shares of Gilead Sciences in a research report issued to clients and investors on Wednesday, August 3rd. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will post earnings per share of $6.70 for the year, up from their previous forecast of $6.60. Cantor Fitzgerald currently has a “Neutral” rating and a $70.00 price target on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $6.58 per share. Cantor Fitzgerald also issued estimates for Gilead Sciences’ FY2023 earnings at $6.72 EPS.
GILD has been the topic of several other reports. Royal Bank of Canada lifted their target price on Gilead Sciences from $76.00 to $77.00 and gave the stock an “outperform” rating in a report on Tuesday, April 12th. SVB Leerink initiated coverage on Gilead Sciences in a research note on Monday, May 23rd. They set a “market perform” rating and a $68.00 price target for the company. Piper Sandler cut their price target on Gilead Sciences from $73.00 to $69.00 and set a “neutral” rating for the company in a research note on Monday, May 16th. StockNews.com downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Finally, BMO Capital Markets initiated coverage on Gilead Sciences in a research note on Tuesday, June 7th. They set a “hold” rating and a $63.00 price target for the company. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $72.07.
Gilead Sciences Stock Down 1.3 %
Hedge Funds Weigh In On Gilead Sciences
Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its holdings in Gilead Sciences by 2.3% during the 1st quarter. BlackRock Inc. now owns 121,709,365 shares of the biopharmaceutical company’s stock valued at $7,235,622,000 after acquiring an additional 2,748,159 shares during the period. State Street Corp raised its holdings in Gilead Sciences by 1.0% during the 1st quarter. State Street Corp now owns 57,970,959 shares of the biopharmaceutical company’s stock valued at $3,446,374,000 after acquiring an additional 601,690 shares during the period. Capital World Investors raised its holdings in Gilead Sciences by 16.0% during the 1st quarter. Capital World Investors now owns 49,501,852 shares of the biopharmaceutical company’s stock valued at $2,942,905,000 after acquiring an additional 6,820,228 shares during the period. Geode Capital Management LLC raised its holdings in Gilead Sciences by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 22,739,179 shares of the biopharmaceutical company’s stock valued at $1,647,123,000 after acquiring an additional 440,695 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Gilead Sciences by 324.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock valued at $1,070,232,000 after acquiring an additional 13,764,169 shares during the period. Hedge funds and other institutional investors own 80.16% of the company’s stock.
Gilead Sciences Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Thursday, September 15th will be paid a $0.73 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $2.92 annualized dividend and a yield of 4.78%. Gilead Sciences’s payout ratio is 89.02%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.